World

Pause in AstraZeneca-Oxford vaccine trial not a setback: UK

Reuters London | Updated on September 09, 2020 Published on September 09, 2020

Health Secretary Matt Hancock says move won’t impact covid vaccine efforts

Britain’s Health Secretary Matt Hancock said on Wednesday that AstraZeneca’s decision to pause its coronavirus vaccine trials was a challenge but would not necessarily set back efforts to develop a vaccine.

AstraZeneca said it had paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant. “It is obviously a challenge to this particular vaccine trial,” Hancock said on Sky News when asked about the pause in the trial. “It’s not actually the first time this has happened to the Oxford vaccine.” Asked whether it would set back the vaccine development process, he said: “Not necessarily, it depends on what they find when they do the investigation.”

 

Read also: AstraZeneca-Oxford University Covid-19 vaccine trial “on pause”

 

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 09, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.